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and analyzed for the treatment phase. In addition, an interim
analysis of the subsequent observation period was conducted.
Patients were treated before the DRG-system was introduced in
Germany. Therefore, length of each hospitalisation was used as
proxy for case-complexity and as criterion for assignment to one
of 3 DRGxs relevant for NHL-patients. Several sensitivity analy-
ses were performed to address different DRG-grouping criteria
and discounting scenarios. RESULTS: Mean cost per treatment
cycle was €2700 for R-MCP and €1900 for MCP (p < 0.0001).
Mean observation periods after end of initial treatment were
21.2 months for R-MCP and 17.6 months for MCP (p = 0.02).
Hospitalisations for adverse events (−32%), new chemotherapies
(−33%), treatment of progressive disease (−55%) and other
reasons (−39%) were reduced in the R-MCP arm. This resulted
in mean, undiscounted cost per patient in the observation period
of €4600 for R-MCP and €7700 for MCP (p = 0.02). To adjust
for the difference in length of the observation period overall
monthly costs were calculated and amounted to €1230 for R-
MCP and €1290 for MCP (p = 0.67). Sensitivity analyses did not
result in major changes. Clinically, R-MCP resulted in an objec-
tive response rate of 85.6% vs. 65.5% with MCP. After two
years event free survival for R-MCP was 69% vs. 44% for MCP
alone (p < 0.001). CONCLUSION: Initially higher treatment
costs of R-MCP were compensated by savings due to better efﬁ-
cacy. Combined with the clinical superiority of R-MCP, this
regime is likely to prevail as the dominant treatment strategy
compared to MCP alone at the ﬁnal analysis.
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OBJECTIVES: In breast cancer, primary prophylaxis with peg-
ﬁlgrastim has been shown to improve health outcomes but its
cost-effectiveness has not been evaluated in the French setting.
Filgrastim is often used for less than the recommended 11 days
(e.g., 5–6 days), which has been associated with sub-optimal out-
comes. This study compared the cost-effectiveness of pegﬁlgras-
tim versus 11- and 6-day ﬁlgrastim primary prophylaxis in
women with stage I–III breast cancer receiving chemotherapy
with moderate to high FN risk in France. METHODS: A deci-
sion-analytic model was constructed from a health care payer’s
perspective. Costs included drugs, drug administration, FN-
related hospitalizations and subsequent costs, and were based on
ex-factory price listing and DRG Tariff. Effectiveness was mea-
sured as FN avoided and life-year-gained (LYG). FN risk (varied
by days of ﬁlgrastim), FN case-fatality, relative dose intensity
(RDI), and the impact of RDI on survival were based on a com-
prehensive literature review and expert panel validation. Breast
cancer mortality and all-cause mortality were taken from ofﬁcial
statistics. Model robustness was tested using sensitivity analyses.
RESULTS: Compared with 11 days of ﬁlgrastim, pegﬁlgrastim
saved costs and was more effective. Compared with 6-day 
ﬁlgrastim, pegﬁlgrastim avoided 10.5 absolute percentage point
of FN (17.5% vs. 7%). The incremental cost-effectiveness 
ratio (ICER) was €10,295 per FN avoided. The average life
expectancy was 16.27 years with pegﬁlgrastim and 16.16 years
with ﬁlgrastim, yielding an ICER of €9652/LYG. Age of diag-
nosis and cancer stage had minimal impact on the results. Key
inﬂuencing factors included relative costs of drugs and relative
risk of FN. CONCLUSIONS: Use of pegﬁlgrastim in France may
dominate 11-day use of ﬁlgrastim and is cost-effective compared
to 6-day use of ﬁlgrastim. The cost-effectiveness ratio is signiﬁ-
cantly below the commonly used threshold for cost-effectiveness
ratios in Europe.
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TREATMENT OF ACTINIC KERATOSIS (AK) AND BASAL CELL
CARCINOMA (BCC) WITH METVIX® (MAL-PDT) IN REAL LIFE
PRACTICE: A COST OF ILLNESS AND MODEL VALIDATION
STUDY
Caekelbergh K,Annemans L
IMS Health Economics and Outcomes Research (HEOR), Brussels,
Belgium
OBJECTIVES: An original decision model has shown that
methyl-aminolevulinate (MAL) is a cost-effective intervention in
AK and better value for money than excision in BCC. The objec-
tive of this observational study was to conﬁrm these results in
real life in Belgium from a health-care-payers perspective.
METHODS: The study was a prospective, multi-centre obser-
vational study in which patients meeting criteria for MAL-
treatment were followed for 6 months after ﬁrst application of
methyl-aminolevulinate. Clinical response (CR) and cosmetic
outcome (CO) were evaluated at the last available visit during
the follow-up period. Socio-demographic data, treatment related
data and safety data were collected. Inclusion period was
October 2004–October 2005. RESULTS: 247 patients were eval-
uated (mean age: 69 years; 53% males). 47% of patients had AK
with an average of 7.1 ± 0.4 lesions (32% new lesions); BCC-
patients had an average of 1.7 ± 0.2 lesions (89% new lesions).
As the majority of patients had multiple lesions, on average
0.797 tube of MAL was used per patient. AK patients had a
mean of 3.9 dermatologist visits related to diagnosis, treatment
and follow-up (BCC: 4.2 visits). In 83% of AK and in 84% of
BCC patients, all lesions showed a complete CR. Good to excel-
lent CO was found in 95% and 93% of AK and BCC patients
respectively. Total cost of care (MAL-treatment plus follow-up)
was €383 in AK and €298 in BCC-patients, with a higher effec-
tiveness compared to the model. The model showed €255 for AK
and €303 for BCC. Higher costs in AK were due to a higher
mean number of lesions per patient compared to the model pop-
ulation (4.1 lesions per patient). CONCLUSIONS: This obser-
vational study conﬁrms the cost-effectiveness shown in the
original model for methyl-aminolevulinate in AK and BCC and
shows that real-life data can be used to reﬁne original decision
models.
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PHARMACOECONOMIC ANALYSIS IN SPAIN OF THERAPY
WITH ERLOTINIB, DOCETAXEL, PEMETREXED OR BEST
SUPPORTIVE CARE IN PATIENTS WITH ADVANCED NON-
SMALL CELL LUNG CANCER WHO HAVE FAILED PREVIOUS
CHEMOTHERAPY REGIMENS
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OBJECTIVE: To compare the cost-effectiveness of therapy with
erlotinib (ERL), docetaxel (DOC), pemetrexed (PEM) or best
supportive care (BSC) in patients with advanced non-small cell
lung cancer (NSCLC) in Spain. METHODS: A Markov model
with 3 health states (progression free, disease progression and
dead) was developed. Time horizon: 2 years (monthly cycles).
Survival and time to progression were obtained from 3 clinical
trials. Utilities were obtained from a study performed in UK in
154 patients. National Health System (NHS) perspective (direct
health costs) was applied. Resources used were estimated from
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a panel of Spanish oncologists and from the literature. Unit costs
were derived from Spanish databases (€ March 2006). Annual
discount rate: 3.5% (costs and utilities). Sensitivity analyses for
subpopulations, 3 years results (Weibull and Loglogistic distrib-
utions) and probabilistic (Monte Carlo) were performed.
RESULTS: After 2 years more QALY per patient were obtained
with ERL (0.24) than with DOC (0.23) and BSC (0.18). No dif-
ferences versus PEM were observed. The total cost per patient
was lower with ERL (€17,838) than with DOC (€20,392; 
€−2554) or PEM (€27,317; €−9479) and higher than with BSC
(€8198; €+9640). ERL was the “dominant” treatment (more efﬁ-
cacy and lower costs) versus DOC and resulted in a cost saving
versus PEM. Additional cost per QALY or life year gained with
ERL versus BSC: €160,667 and €56,706, respectively. The 
sensitivity analysis conﬁrmed the robustness of the base case
analysis. If 1000 NSCLC patients were treated with ERL, the
annual saving for NHS (substitution rates: 5%–65%) would
range between €123,000–€1,600,000 (DOC replacement) and
€448,000–€5,831,000 (PEM replacement). CONCLUSIONS:
According to this model, advanced NSCLC treatment with ERL
is more cost-effective than with DOC and PEM, with savings for
the NHS.
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COST-EFFECTIVENESS AND COST-UTILITY OF FENTANYL
TTS (DUROGESIC® 25, 50) VS. SR/IR ORAL MORPHINES IN THE
MANAGEMENT OF CHRONIC CANCER PAIN
Estevez-Carrizo FE
University of Montevideo, Uruguay, Montevideo, Uruguay
OBJECTIVES: Chronic cancer pain has a devastating impact on
quality of life. This leads to an increase in heathcare services uti-
lization. The objective of the present study is to estimate the cost-
efectiveness and cost-utility quotients of Fentanyl TTS treatment
related to SR oral Morphine or IR oral Morphine in patients
with moderate-severe chronic cancer pain. METHODS:
Designed from the perspective of the health care provider, with
a 12 weeks horizon and a pharmacoeconomic decision making
model (decision tree). Cost-effectiveness relationship estimates
was $15 per day of pain control (DPC) for Fentanyl TTS , $.3
per DPC for sustained-release Morphine and $6.4 per DPC for
immediate release Morphine. Cost-utility relationship estimates
was $23.1 per Quality Adjusted DPC (QALD) for Fentanyl TTS,
$18.9 per QALD for sustained-release Morphine and $53.6 per
QALD for immediate realease Morphine. This means that the
cost of a QALD when treating patients with Fentanyl TTS is
similar that patients treated with SR Morphine and less than half
of patients treated with IR Morphine. RESULTS: The incre-
mental cost-effectiveness relationship (ICER) for Fentanyl TTS
vs. SR Morphine was of $20,2 per extra DPC, while the ICER
for Fentanyl TTS vs. IR Morphine was $26.1 per extra QALD.
The incremental cost-utility relationship (ICUR) for Fentanyl
TTS vs. Sustained-release Morphine was $24.9 per extra QALD
and of $19.2 per extra QALD for Fentanyl TTS vs. IR Morphine.
The pharmacoeconomic model constructed for the analysis was
duly validated through a one way sensitivity analysis. 
CONCLUSIONS: We concluded, compared to oral Morphines,
Femtanyl TTS is a cost-effective choice for the treatment of mod-
erate-severe cancer pain. The present analysis allows to draw the
conclusion that the better efﬁciency of this new transdermal
pharmaceutical form of Fentanyl, is mainly due to an improve-
ment in qualtiy of life.
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SHOULD FOTEMUSTINE BE USED AS THE FIRST 
LINE TREATMENT
Faluta T, Czech M, Pachocki R
Servier Polska, Warsaw, Poland
OBJECTIVE: Dacarbazine is routinely used as the ﬁrst line treat-
ment of disseminated malignant melanoma with brain metas-
tases in Poland. A head-to-head randomized controlled trial
(RCT) showed a clinical superiority of fotemustine over dacar-
bazine in this indication. At the same time patients’ access to
many innovative medicines in Poland is limited because of bud-
getary constraints. Even if an innovative medicine is more effec-
tive and cost-effective, it is not applied since it is more expensive
for the health care budget. The main objective of this analysis is
to verify whether an administration of fotemustine is econom-
icly justiﬁed for the National Health Fund (NHF)—the public
payer in Poland. METHODS: A cost-minimization analysis was
carried out from the NHF point of view. Direct medical costs
were divided according to accounting standards into two groups:
cost of drugs and cost of hospitalization required in order to
administer the drugs. The majority of unit prices used in calcu-
lations were derived from the ofﬁcial price list of the Pomeran-
ian Sickness Fund (which is the NHF part now). Following
clinical standards and the length of the RCT the time horizon is
26 weeks. RESULTS: The cost of fotemustine administered to
one patient (€4700) is higher than the cost of dacarbazine (€676)
by €4024. The cost of hospitalization necessary to administer
dacarbazine amounts to €5884 and is higher than cost for fote-
mustine (€1284) by €4600. The total cost in fotemustine group
amounts to €598 and was lower than cost of dacarbazine
(€6560) by €576. CONCLUSION: Substitution of dacarbazine
with fotemustine in the treatment of disseminated malignant
melanoma with brain metastases is a good alternative not only
for Polish patients (as clinically better) but also for the Polish
NHF (as cost–saving). Ex. rate 1 € = 3.98 PLN.
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OBJECTIVES: Oxaliplatin solution form is a new and safer for-
mulation of oxaliplatin avoiding the reconstitution step during
cytotoxic preparation. The main objective was to assess the eco-
nomic impact using oxaliplatin concentrated solution compared
with the lyophilised powder form from the hospital pharmacy
point of view. METHODS: Due to the equivalent efﬁcacy
between the 2 formulations, a cost-minimisation analysis with a
hospital perspective was performed comparing the solution
versus the powder. A single-centre observational study was con-
ducted in a French Cancer Centre. The cytotoxic preparations
were assessed using the powder in a ﬁrst time and the solution
form in a second time. The same staff member manipulated both
preparations in order to avoid any bias. Two independent
observers collected the results from the 30 manipulations. The
ﬁrst endpoint assessed was preparation time. Secondary endpoint
was overall cost associated with this preparation, which included
costs associated to preparation time, material and cytotoxic
waste management. RESULTS: The reconstitution step was
avoided using the solution form. The time saved with the solu-
tion form versus the lyophilised powder was 139 seconds per
preparation. The overall avoided cost represented €1.04 per
preparation using oxaliplatin solution form. This total cost could
